DelveInsight’s ‘Chronic Kidney Disease Pipeline Insight 2023‘ report provides comprehensive global coverage of pipeline Chronic Kidney Disease therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Chronic Kidney Disease pipeline domain.
For Chronic Kidney Disease emerging drugs, the Chronic Kidney Disease pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.
Key Takeaways from the Chronic Kidney Disease Pipeline Report
- DelveInsight’s Chronic Kidney Disease Pipeline analysis depicts a robust space with 76+ active players working to develop 80+ pipeline therapies for Chronic Kidney Disease treatment.
- The leading Chronic Kidney Disease companies include Boehringer Ingelheim, Eli Lilly and Company, Reata Pharmaceuticals, Novo Nordisk, KBP Biosciences, AstraZeneca, Allena Pharmaceuticals, SCOHIA PHARMA, DiaMedica Therapeutics, CinCor Pharma, Galapagos NV, Sentien Biotechnologies, Inc., Regeneron Pharmaceuticals, UnicoCell Biomed, OccuRx, Pharmicell, Lisata Therapeutics, Unicycive Therapeutics, Senda Biosciences, Sarfez Pharmaceuticals, Rege Nephro, Orgenesis, GNI Group, Algomedix, Maze Therapeutics, Chinook Therapeutics, Angion Biomedica Corp, Arch Biopartners, Scohia Pharma, Algernon Pharmaceuticals, TICEBA GmbH, and others are evaluating their lead assets to improve the Chronic Kidney Disease treatment landscape.
- Key Chronic Kidney Disease pipeline therapies in various stages of development include Empagliflozin, Bardoxolone methyl, Ziltivekimab, KBP-5074, AZD9977, ALLN-346, BI-685509, SCO-792, DM199, Baxdrostat, GLPG2737, SBI-101, REGN5459, ELIXCYTE, FT011, Cellgram-CKD, CLBS201, UNI-494, Research Program, SZ007, Renal progenitor cells, MSCKD, F351, Research programme: TRPC6 antagonist, APOL1 Programme, Research and discovery programs: severe chronic kidney disease, ROCK2 Inhibitor, LSALT peptide, SCO-116, Repirinast, and others.
- In March 2023, POXEL SA, announced the publication of preclinical results in autosomal dominant polycystic kidney disease (ADPKD) for PXL770, a novel, first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator. For the first time, POXEL SA showed beneficial effects of a direct and selective AMPK activator in preclinical ADPKD models from three species: mouse, human, and dog. These results confirm the potential utility of AMPK activation for this disease and support the development of PXL770 in the Phase 2 clinical program for ADPKD.
- In February 2023, AstraZeneca announced the successful completion of the acquisition of CinCor Pharma, Inc. The acquisition bolsters AstraZeneca’s cardiorenal pipeline by adding baxdrostat (CIN-107), an aldosterone synthase inhibitor (ASI) for blood pressure lowering in treatment-resistant hypertension, to its cardiorenal portfolio.
Request a sample and discover the recent breakthroughs happening in the Chronic Kidney Disease pipeline landscape @ Chronic Kidney Disease Pipeline Outlook
Chronic Kidney Disease Overview
Chronic Kidney Disease occurs when the kidneys are damaged and unable to filter blood. As a result, additional blood fluid and waste linger in the body, potentially contributing to a variety of health problems such as heart disease and stroke. The severity of Chronic Kidney Disease varies. It normally worsens over time, but treatment has been demonstrated to reduce the progression. If CKD is not treated, it can lead to renal failure and early cardiovascular disease.
Chronic kidney disease is more common in the elderly. In the United States, it is the leading cause of death. It is believed that 37 million US adults have chronic kidney disease, with the majority going undetected. Early stage kidney disease typically has no symptoms, and many people are unaware they have CKD until it is well advanced. Kidney disease frequently worsens over time and can lead to kidney failure as well as other health issues such as a stroke or heart attack. End-stage kidney disease (ESKD), which is treated with a kidney transplant or dialysis, affects around 2 in 1,000 Americans.
Find out more about Chronic Kidney Disease medication @ New Drug for Chronic Kidney Disease
Chronic Kidney Disease Treatment Analysis: Drug Profile
KBP-5074: KBP Biosciences
KBP-5074, a possibly best-in-class, next-generation, non-steroidal MRA discovered and developed by KBP scientists, is being developed globally to first treat Stage 3b/4, or moderate-to-severe, CKD patients with uncontrolled hypertension. KBP-5074 binds to recombinant human MRs with much higher affinity than recombinant human glucocorticoid, progesterone, and androgen receptors, implying that it should be effective in blocking the hypertensive and renal tissue-damaging effects of aldosterone while reducing the risk of pro-diabetic and adverse endocrine effects. To date, clinical trials have shown that it can lower blood pressure without causing androgenic side effects including hirsutism, obesity, or gynecomastia. The drug is currently being tested in Phase III trials for the treatment of people with uncontrolled hypertension and Moderate or Severe CKD.
Ziltivekimab: Novo Nordisk
Ziltivekimab is a patented anti-interleukin-6 ligand monoclonal antibody (anti-IL6 mAb) that is used to treat patients with severe chronic kidney disease (CKD). Ziltivekimab is a medication being investigated to lower the incidence of significant cardiovascular adverse events in people with chronic kidney disease (CKD) who have atherosclerotic cardiovascular disease (ASCVD) and inflammation. Patients with moderate to severe CKD, ASCVD, and inflammation are at high risk for an adverse cardiovascular event, and there are no licensed medications to reduce this risk. With data from human genetic research and preclinical investigations, the proinflammatory cytokine interleukin-6 (IL-6) has been proven to be an independent, causative cause of ASCVD. The drug is currently in Phase III testing for the treatment of moderate to severe chronic kidney disease.
Key Chronic Kidney Disease Therapies and Companies
- Empagliflozin: Boehringer Ingelheim/Eli Lilly and Company
- Bardoxolone methyl: Reata Pharmaceuticals
- KBP-5074: KBP Biosciences
- Ziltivekimab: Novo Nordisk
- US-APR2020: Kibow Pharma
- DM199: DiaMedica Therapeutics
- Sucunamostat: SCOHIA PHARMA/Takeda
- AL-01211: AceLink Therapeutics
Learn more about the novel and emerging Chronic Kidney Disease pipeline therapies @ Chronic Kidney Disease Clinical Trials
Chronic Kidney Disease Therapeutics Assessment
- By Product Type
-
- Monotherapy
- Combination Therapy
- By Stage
-
- Discovery
- Pre-Clinical
- Phase I
- Phase II
- Phase III
- Pre-registration
- By Route of Administration
-
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
- By Molecule Type
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
Scope of the Chronic Kidney Disease Pipeline Report
- Coverage: Global
- Key Chronic Kidney Disease Companies: Boehringer Ingelheim, Eli Lilly and Company, Reata Pharmaceuticals, Novo Nordisk, KBP Biosciences, AstraZeneca, Allena Pharmaceuticals, SCOHIA PHARMA, DiaMedica Therapeutics, CinCor Pharma, Galapagos NV, Sentien Biotechnologies, Inc., Regeneron Pharmaceuticals, UnicoCell Biomed, OccuRx, Pharmicell, Lisata Therapeutics, Unicycive Therapeutics, Senda Biosciences, Sarfez Pharmaceuticals, Rege Nephro, Orgenesis, GNI Group, Algomedix, Maze Therapeutics, Chinook Therapeutics, Angion Biomedica Corp, Arch Biopartners, Scohia Pharma, Algernon Pharmaceuticals, TICEBA GmbH, and others.
- Key Chronic Kidney Disease Pipeline Therapies: Empagliflozin, Bardoxolone methyl, Ziltivekimab, KBP-5074, AZD9977, ALLN-346, BI-685509, SCO-792, DM199, Baxdrostat, GLPG2737, SBI-101, REGN5459, ELIXCYTE, FT011, Cellgram-CKD, CLBS201, UNI-494, Research Program, SZ007, Renal progenitor cells, MSCKD, F351, Research programme: TRPC6 antagonist, APOL1 Programme, Research and discovery programs: severe chronic kidney disease, ROCK2 Inhibitor, LSALT peptide, SCO-116, Repirinast, and others.
Dive deep into rich insights for drugs used for Chronic Kidney Disease treatment; visit @ Chronic Kidney Disease Drugs
Table of Contents
| 1. | Introduction |
| 2. | Executive Summary |
| 3. | Chronic Kidney Disease Pipeline: Overview |
| 4. | Analytical Perspective In-depth Commercial Assessment |
| 5. | Chronic Kidney Disease Pipeline Therapeutics |
| 6. | Chronic Kidney Disease Pipeline: Late Stage Products (Phase III) |
| 7. | Chronic Kidney Disease Pipeline: Late Stage Products (Phase III) |
| 8. | Chronic Kidney Disease Pipeline: Mid-Stage Products (Phase II) |
| 9. | Chronic Kidney Disease Pipeline: Early Stage Products (Phase I) |
| 10. | Therapeutic Assessment |
| 11. | Inactive Products |
| 12. | Company-University Collaborations (Licensing/Partnering) Analysis |
| 13. | Key Companies |
| 14. | Key Products |
| 15. | Unmet Needs |
| 16. | Market Drivers and Barriers |
| 17. | Future Perspectives and Conclusion |
| 18. | Analyst Views |
| 19. | Appendix |
For further information on the Chronic Kidney Disease therapy in the pipeline, reach out @ Chronic Kidney Disease Medication
Related Reports
Chronic Kidney Disease Epidemiology Forecast
Chronic Kidney Disease Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted chronic kidney disease epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Chronic Kidney Disease Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key chronic kidney disease companies, including ProKidney, Reata Pharmaceuticals, Inc., Novo Nordisk A/S, Boehringer Ingelheim, Eli Lilly and Company, KBP Biosciences, Kibow Pharma, Cincor Pharma, among others.
Moderate and Severe Chronic Kidney Disease Market
Moderate and Severe Chronic Kidney Disease Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key moderate and severe chronic kidney disease companies, including Kibow Pharma, Bayer, Roche, Caladrius Biosciences, UnicoCell Biomed, Pharmicell, Scohia Pharma, Unicycive Therapeutics, among others.
Moderate and Severe Chronic Kidney Disease Pipeline
Moderate and Severe Chronic Kidney Disease Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key moderate and severe chronic kidney disease companies, including Kibow Pharma, Bayer, Roche, Caladrius Biosciences, UnicoCell Biomed, Pharmicell, Scohia Pharma, Unicycive Therapeutics, among others.
Anemia In Chronic Kidney Disease Market
Anemia In Chronic Kidney Disease Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key anemia in chronic kidney disease companies, including Biocad, Xenetic Biosciences, Chiasma, Liminal BioSciences, among others.
Anemia In Chronic Kidney Disease Pipeline
Anemia In Chronic Kidney Disease Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key anemia in chronic kidney disease companies, including Biocad, Xenetic Biosciences, Chiasma, Liminal BioSciences, among others.
Other Trending Reports
Human Papilomavirus Market | Eczema Market | Prefilled Syringes Market | Capnography Device Market | Alopecia Market | Parkinson’s Disease Market | Hyperhidrosis Market | Defibrillators Market | Concussions Market Size | Pulse Oximeters Market | Acral Lentiginous Melanoma Market | Malt Lymphoma Market | Rhino Conjunctivitis Market | Defibrillators Market | Pulse Oximeters Market | Angioedema Market | Alopecia Aerata Market | Alopecia Areata Market | Bipolar Depression Market | Capnography Device Market | Bone And Joint Infection Market | Brain Aneurysm Stents Market | Hearing Aid Devices Market | Immunologic Deficiency Syndrome Market | Radiation Toxicity Market | Advanced Cancer Pain Management Market | Alport Syndrome Market | Pain Management Devices Market | Polycythemia Market | Vertigo Market | Actinic Keratosis Market | Acute Pulmonary Embolism Market | Ambulatory Arrhythmia Monitoring Devices Market | Aortic Stenosis Market | Chemotherapy Induced Thrombocytopenia Market | Dysthymia Market | Human Papillomavirus Positive Cancer Market | Onycholysis Market | Penicillinbinding Proteins Market | Postsurgical Pain Market
Related Healthcare Services
- Healthcare Consulting
- Healthcare Competitive Intelligence Services
- Healthcare Asset Prioritization Services
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Connect With Us at LinkedIn | Facebook | Twitter
Contact Us
Sandeep Joshi
info@delveinsight.com
+1(919)321-6187